Phreesia saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 88 to 91.

As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength. IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.

Over 100 years of market history shows that the stocks that go on to make the biggest gains often have an RS Rating north of 80 at the beginning of a new climb.

Looking For The Best Stocks To Buy And Watch? Start Here

Phreesia is not currently offering a proper buying opportunity. See if the stock goes on to build a promising consolidation that could spark a new run.

While the company's bottom line growth dropped last quarter from 0% to -182%, the top line grew 46%, up from 45% in the previous report.

Phreesia holds the No. 12 rank among its peers in the Computer Software-Medical industry group. Doximity, Inovalon and Optimizerx are among the top 5 highly rated stocks within the group.